Genmab has been granted a patent for novel heterodimeric antibody-Fc-containing proteins, including bispecific antibodies, and innovative methods for their production. The patent covers a heterodimeric antibody with specific Fc regions from human IgG4, showcasing advancements in antibody technology. GlobalData’s report on Genmab gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Genmab AS - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Genmab, Personalized cancer vaccines was a key innovation area identified from patents. Genmab's grant share as of February 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for novel bispecific antibodies with unique fc regions

Source: United States Patent and Trademark Office (USPTO). Credit: Genmab AS

A recently granted patent (Publication Number: US11866514B2) discloses a novel heterodimeric antibody design. The antibody comprises two heavy chains, with each chain having a different Fc region derived from human IgG4. The first Fc region includes a specific CH3 region, while the second Fc region contains amino acid substitutions at positions 405 and 409. Notably, the sequences of the CH3 regions in the two heavy chains are distinct, allowing them to bind different epitopes. Additionally, the antibody includes two full-length light chains and a unique hinge region sequence, making it a promising candidate for therapeutic applications.

Furthermore, the patent covers the method for producing the heterodimeric antibody, involving the co-expression of nucleic acid constructs in a host cell to obtain the desired antibody. The process includes specific steps such as providing nucleic acid constructs for the heavy chains, expressing them in a host cell, and obtaining the heterodimeric antibody from the cell culture. The resulting antibody can be further modified by introducing additional nucleic acid constructs encoding light chains. The patent also extends to pharmaceutical compositions containing the heterodimeric antibody along with a pharmaceutically-acceptable carrier, emphasizing its potential for use in therapeutic formulations. Overall, the patent highlights a novel antibody design with unique features that could have significant implications in the field of biopharmaceuticals and targeted therapies.

To know more about GlobalData’s detailed insights on Genmab, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies